The role of mast cell tryptases in cardiac myxoma: Histogenesis and development of a challenging tumor

Donato,Giuseppe; Conforti,Francesco; Camastra,Caterina; Ammendola,Michele; Donato,Annalidia; Renzulli,Attilio

doi:10.3892/ol.2014.2104

The role of mast cell tryptases in cardiac myxoma: Histogenesis and development of a challenging tumor

Authors:
- Giuseppe Donato
- Francesco Conforti
- Caterina Camastra
- Michele Ammendola
- Annalidia Donato
- Attilio Renzulli
View Affiliations

Affiliations: Department of Pathology, School of Medicine, University Magna Graecia, Catanzaro I‑88100, Italy, Department of Pharmacology and 3Cardiac Surgery, School of Medicine, University Magna Graecia, Catanzaro I‑88100, Italy, Department of Cardiac Surgery, School of Medicine, University Magna Graecia, Catanzaro I‑88100, Italy
Published online on: April 29, 2014 https://doi.org/10.3892/ol.2014.2104
Pages: 379-383

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A number of available studies have focused on the role of mastocytes and their angiogenic factors, such as tryptase expression, in cancer growth as a major research objective. Cardiac myxoma is a rare neoplasia and is the most common primary tumor of the heart. The cellular elements of cardiac myxoma have an endothelial phenotype; however, its histogenesis remains unclear. Currently, no available studies have correlated the pathological characteristics of cardiac myxomas, such as cell differentiation and vascularization, with the angiogenic factors of mast cells. The aim of the present study was to investigate the role of mast cell tryptases on the development of cardiac myxomas and examine the histogenesis of tumoral cells. A series of 10 cardiac myxomas were examined by immunohistochemical analysis for the presence of tryptase‑positive mast cells. Statistical analysis of our data demonstrated that angiogenesis and the development of pseudovascular structures were correlated with the number of tryptase‑positive mast cells. Therefore, we hypothesize that cardiac myxoma cells are endothelial precursors which are able to generate mature vascular structures. Further morphological and immunophenotypic analyses of tumoral cells may corroborate such a hypothesis.

View Figures

View References

1	Riberi A, Gariboldi V, Grisoli D, et al: Cardiac tumors. Rev Pneumol Clin. 66:95–103. 2010.
2	Carney JA, Gordon H, Carpenter PC, et al: The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore). 64:270–283. 1985.
3	Rhodes AR, Silverman RA, Harrist TJ, et al: Mucocutaneous lentigines, cardiomucocutaneous myxomas, and multiple blue nevi: the ‘LAMB’ syndrome. J Am Acad Dermatol. 10:72–82. 1984.
4	Burke AP, Tazeelar H, Gomez-Roman JJ, et al: Benign tumours of pluripotent mesenchyme. World Health Organization Tumours of the Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: IARC Press; Lyon: pp. 260–265. 2004
5	Ribatti D and Crivellato E: The controversial role of mast cells in tumor growth. Int Rev Cell Mol Biol. 275:89–131. 2009.
6	Ribatti D, Crivellato E, Roccaro AM, et al: Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy. 34:1660–1664. 2004.
7	Benitez-Bribiesca L, Wong A, Utrera D, et al: The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem. 49:1061–1062. 2001.
8	McNeil HP, Adachi R and Stevens RL: Mast cell-restricted tryptases: structure and function in inflammation and pathogen defense. J Biol Chem. 282:20785–20789. 2007.
9	Ammendola M, Zuccala V, Patruno R, et al: Tryptase-positive mast cells and angiogenesis in keloids: a new possible post-surgical target for prevention. Updates Surg. 65:53–57. 2013.
10	Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 324:1–8. 1991.
11	Acebo E, Val-Bernal JF and Gomez-Roman JJ: Thrombomodulin, calretinin and c-kit (CD117) expression in cardiac myxoma. Histol Histopathol. 16:1031–1036. 2001.
12	Arock M, Schneider E, Boissan M, et al: Differentiation of human basophils: an overview of recent advances and pending questions. J Leukoc Biol. 71:557–564. 2002.
13	Sperr WR, Bankl HC, Mundigler G, et al: The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. Blood. 84:3876–3884. 1994.
14	Donato G, Conforti F, Zuccala V, et al: Expression of tenascin-c and CD44 receptors in cardiac myxomas. Cardiovasc Pathol. 18:173–177. 2009.
15	Orlandi A, Ciucci A, Ferlosio A, et al: Cardiac myxoma cells exhibit embryonic endocardial stem cell features. J Pathol. 209:231–239. 2006.
16	Zhou Y, Pan P, Yao L, et al: CD117-positive cells of the heart: progenitor cells or mast cells? J Histochem Cytochem. 58:309–316. 2010.
17	Harris IS and Black BL: Development of the endocardium. Pediatr Cardiol. 31:391–399. 2010.
18	Milgrom-Hoffman M, Harrelson Z, Ferrara N, et al: The heart endocardium is derived from vascular endothelial progenitors. Development. 138:4777–4787. 2011.
19	Andrews RG, Singer JW and Bernstein ID: Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood. 67:842–845. 1986.
20	Krause DS, Fackler MJ, Civin CI, et al: CD34: structure, biology, and clinical utility. Blood. 87:1–13. 1996.
21	Nielsen JS and McNagny KM: CD34 is a key regulator of hematopoietic stem cell trafficking to bone marrow and mast cell progenitor trafficking in the periphery. Microcirculation. 16:487–496. 2009.
22	van Beijnum JR, van der Linden E and Griffioen AW: Angiogenic profiling and comparison of immortalized endothelial cells for functional genomics. Exp Cell Res. 314:264–272. 2008.
23	Siemerink MJ, Klaassen I, Vogels IM, et al: CD34 marks angiogenic tip cells in human vascular endothelial cell cultures. Angiogenesis. 15:151–163. 2012.
24	Theoharides TC and Conti P: Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol. 25:235–241. 2004.
25	Dyduch G, Kaczmarczyk K and Okon K: Mast cells and cancer: enemies or allies? Pol J Pathol. 63:1–7. 2012.
26	Ribatti D, Finato N, Crivellato E, et al: Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer. Am J Obstet Gynecol. 193:1961–1965. 2005.
27	Takanami I, Takeuchi K and Naruke M: Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer. 88:2686–2692. 2000.
28	Ammendola M, Sacco R, Donato G, et al: Mast cell positivity to tryptase correlates with metastatic lymph nodes in gastrointestinal cancer patients treated surgically. Oncology. 85:111–116. 2013.
29	Ribatti D, Guidolin D, Marzullo A, et al: Mast cells and angiogenesis in gastric carcinoma. Int J Exp Pathol. 91:350–356. 2010.
30	Groot Kormelink T, Abudukelimu A and Redegeld FA: Mast cells as target in cancer therapy. Curr Pharm Des. 5:1868–1878. 2009.